These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18194710)

  • 1. Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment.
    Cavanagh WA; Tjoa BA; Ragde H
    Urology; 2007 Dec; 70(6 Suppl):36-41. PubMed ID: 18194710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors.
    Tong Y; Song W; Crystal RG
    Cancer Res; 2001 Oct; 61(20):7530-5. PubMed ID: 11606390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers.
    Mann DL; Celluzzi CM; Hankey KG; Harris KM; Watanabe R; Hasumi K
    Ann N Y Acad Sci; 2009 Sep; 1174():41-50. PubMed ID: 19769735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
    Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
    Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic anti-cancer chemotherapy as an emerging concept.
    Haynes NM; van der Most RG; Lake RA; Smyth MJ
    Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
    Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
    Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells--why can they help and hurt us.
    Schäkel K
    Exp Dermatol; 2009 Mar; 18(3):264-73. PubMed ID: 19183400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Witch hunt against tumor cells enhanced by dendritic cells.
    Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
    Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell immunobiology and potential roles in immunotherapy.
    Fadilah SA; Cheong SK
    Malays J Pathol; 2007 Jun; 29(1):1-18. PubMed ID: 19108040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells from bench to bedside and back.
    Adema GJ
    Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
    Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
    Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.